Sugi Predict

Sugi Predict / Targets / BAP1

BAP1

Ubiquitin carboxyl-terminal hydrolase BAP1 · Q92560 · BAP1 on Sugi Atlas →

962 patent compounds predicted against BAP1, 744 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19635942 SCHEMBL19635942 0.64 2/20
SCHEMBL8289768 SCHEMBL8289768 0.52 2/20
SCHEMBL1717790 SCHEMBL1717790 1.00 1/20
SCHEMBL15606890 SCHEMBL15606890 0.98 1/20
SCHEMBL17130651 SCHEMBL17130651 0.81 1/20
SCHEMBL15606905 SCHEMBL15606905 0.80 1/20
SCHEMBL3329695 SCHEMBL3329695 0.79 1/20
SCHEMBL3320699 SCHEMBL3320699 0.78 1/20
SCHEMBL1718407 SCHEMBL1718407 0.78 1/20
SCHEMBL1718482 SCHEMBL1718482 0.77 1/20
SCHEMBL1719735 SCHEMBL1719735 0.76 1/20
SCHEMBL3320927 SCHEMBL3320927 0.76 1/20
SCHEMBL1718955 SCHEMBL1718955 0.75 1/20
SCHEMBL3324053 SCHEMBL3324053 0.75 1/20
SCHEMBL1718460 SCHEMBL1718460 0.75 1/20
SCHEMBL1718294 SCHEMBL1718294 0.75 1/20
SCHEMBL1718614 SCHEMBL1718614 0.74 1/20
SCHEMBL3325678 SCHEMBL3325678 0.74 1/20
SCHEMBL10953920 SCHEMBL10953920 0.73 1/20
SCHEMBL3266248 SCHEMBL3266248 0.73 1/20

Clinical trials — most relevant to BAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Melatonin for Uveal Melanoma PHASE3RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) PHASE2COMPLETED
Olaparib in People With Malignant Mesothelioma PHASE2COMPLETED
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma PHASE2COMPLETED
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas PHASE1/PHASE2RECRUITING
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma nanUNKNOWN
Clinical and Histopathologic Characteristics of BAP1 Mutations nanCOMPLETED
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals nanRECRUITING
Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays nanCOMPLETED
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) nanACTIVE_NOT_RECRUITING
A Prospective Natural History Study in Uveal Melanoma nanACTIVE_NOT_RECRUITING
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico nanCOMPLETED
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma nanRECRUITING
A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer nanUNKNOWN
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome nanCOMPLETED
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Cancer in Inherited Bone Marrow Failure Syndromes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BAP1 binder may also engage these)

ProteinNameSimilarity
D3ZHS6 — 1.000 D3ZHS6 →
Q99PU7 — 1.000 Q99PU7 →
Q66JB6 — 0.996 Q66JB6 →
A2VDM8 — 0.996 A2VDM8 →
Q5F3N6 — 0.994 Q5F3N6 →
Q52L14 — 0.993 Q52L14 →
A1L2G3 — 0.988 A1L2G3 →
B2RUR8 — 0.982 B2RUR8 →
Q80TJ7 — 0.981 Q80TJ7 →
Q3KR59 — 0.979 Q3KR59 →
Q8K2L8 — 0.979 Q8K2L8 →
Q5XJV7 — 0.979 Q5XJV7 →
PHF8 Histone lysine demethylase PHF8 0.979 landscape →
C4A0D9 — 0.979 C4A0D9 →
OTUD7B OTU domain-containing protein 7B 0.979 landscape →
Q4VGL6 — 0.979 Q4VGL6 →
Q28C33 — 0.978 Q28C33 →
P49140 — 0.978 P49140 →
Q62925 — 0.978 Q62925 →
P0C090 — 0.977 P0C090 →
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 0.977 landscape →
O70546 — 0.976 O70546 →
Q4KKX4 — 0.976 Q4KKX4 →
KAT2B Histone acetyltransferase KAT2B 0.976 landscape →
Q8WYQ5 — 0.976 Q8WYQ5 →
Q9HBD1 — 0.976 Q9HBD1 →
Q6NUC6 — 0.976 Q6NUC6 →
Q8K4S7 — 0.976 Q8K4S7 →
Q5TC82 — 0.976 Q5TC82 →
Q9C0A6 — 0.976 Q9C0A6 →